NCT00420030View on ClinicalTrials.gov

Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Shock, Cardiogenic
Interventions
DRUG

Abciximab

Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion

Trial Locations (1)

100 34

Cardiocenter, University Hospital Vinohrady, Prague

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Charles University, Czech Republic

OTHER

NCT00420030 - Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock | Biotech Hunter | Biotech Hunter